Trade Kyntra Bio Inc - KYNB CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.21
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$0.44)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$0.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 5.25
• Open: 5.33
• 1-Year Change: -51.5%
• Day's Range: 4.78 - 5.34

Trade Kyntra Bio Inc - KYNB

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.